CenExel Taps Biopharma Veteran Bethany Sensenig as CFO to Fuel U.S. Expansion
Event summary
- Bethany Sensenig appointed CFO & Head of Strategy at CenExel on June 18, 2026.
- Sensenig brings 30 years of biopharma experience, including CFO roles at commercial and clinical-stage companies.
- Most recently led financial and operational scaling at PE-backed Radius Health.
- Appointment follows May 2026 hiring of Sy Pretorius as CEO, part of leadership expansion strategy.
- CenExel aims to become the largest U.S. clinical research site network.
The big picture
CenExel's rapid leadership team expansion signals aggressive ambitions in the consolidating clinical research site network space. The appointments suggest a push toward institutional-scale operations, potentially positioning the company as a major consolidator in an industry facing increasing sponsor demands for standardized, high-quality trial execution. Sensenig's PE experience may prove particularly valuable as CenExel navigates potential acquisition opportunities or investor relations in its growth phase.
What we're watching
- Execution Risk
- Whether Sensenig can translate her PE-backed scaling experience to CenExel's site network model.
- Strategic Scaling
- The pace at which CenExel can expand its U.S. footprint while maintaining operational quality.
- Governance Dynamics
- How the new leadership duo of Sensenig and Pretorius will reshape CenExel's financial and strategic direction.